Microba announces investment from leaders in global precision medicine

Microba announced yesterday that they had received a $4.1m (AUD) strategic investment from global precision medicine company Macrogen. Working together will provide a platform for Microba to scale rapidly and both parties intend to position Microba as the leading microbiome testing company on a global scale.

CEO of Microba, Blake Wills, said that Microba had recognised the achievements of Macrogen in the human DNA sequencing segment over the last two decades and believed Microba could leverage this excellent platform to deliver microbiome services globally.

“It is very pleasing to have a globally recognised precision medicine company endorse Microba through investment and partnership,” he said.

“The growing requirement to deliver high-resolution microbiome analysis is an unmet need which both parties are committed to solving. The unique technology platform of Microba positions the company very well to deliver the solution.”

To read the full release, please see here

Microba CEO, Blake Willis pictured with Kap-Seok Yang, CEO of Macrogen.